Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Waltham, MA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

WALTHAM, Mass., Sept.  02, 2020  (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in Citi's 15th Annual BioPharma Virtual Conference on September 9, 2020 at 1:30 p.m. Eastern Time.  The panel in which the Company will participate is entitled “Emerging Therapies for Psychiatric Disorders.”

Minerva Neurosciences to Present at Citi's 15th Annual BioPharma Virtual Conference

WALTHAM, Mass., Aug.  13, 2020  (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the JMP Securities CNS Forum on August 19, 2020 at 10:30 a.m. Eastern Time. This event will be held virtually.

Minerva Neurosciences to Present at JMP Securities CNS Forum

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q2 2020 Results - Earnings Call Transcript

WALTHAM, Mass., Aug.  03, 2020  (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended June 30, 2020.

Minerva Neurosciences Reports Second Quarter 2020 Financial Results  and Business Updates

Management to host conference call Management to host conference call

Minerva Neurosciences to Report Second Quarter 2020 Financial Results and Business Updates on August 3, 2020

WALTHAM, Mass., July  01, 2020  (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, announced today that it has exercised its right to opt out of its agreement with Janssen Pharmaceutica NV (Janssen) for the future development of seltorexant (MIN-202).

Minerva Neurosciences Exercises Right to Opt Out of Agreement With Janssen for Seltorexant (MIN-202)

Minerva Neurosciences (NERV) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Minerva Neurosciences (NERV) Looks Good: Stock Adds 8.4% in Session

Minerva Neurosciences (NERV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Minerva Neurosciences (NERV) Stock Stands Out in a Strong Industry

The biotech's shares are mounting a modest comeback after their ugly decline on Friday.

Why Minerva Neurosciences Is Heading Higher Today

The company's lead drug candidate flopped in a phase 3 trial. Can a longer-term follow-up study resurrect the asset?

Here's Why Minerva Neurosciences Collapsed Today

Minerva Neurosciences (NERV) is seeing NERV stock nosedive on Friday after announcing results from a recent schizophrenia study.
The post Minerva Neurosciences: NERV Stock Plummets 72% on Schizophrenia Study appeared first on InvestorPlace.

Minerva Neurosciences: NERV Stock Plummets 72% on Schizophrenia Study

Shares of Minerva Neurosciences Inc. NERV, -66.59% plummeted 67% toward a 7-month low in morning trading Friday, enough to pace all Nasdaq losers, after the biopharmaceutical company announced disappointing results from a phase 3 trial of its schizophrenia treatment.

Minerva Neurosciences' stock plummets after schizophrenia treatment disappoints in phase 3 study

Avenue Therapeutics

Concert Pharma

MEI Pharma

Ocular Therapeutix

Small Drug Industry Prospects Bright Amid Coronavirus Gloom

Black Diamond Therapeutics

Sprout Social

Zynex Inc

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

5 Stocks With Recent Price Strength Amid Disappointing Data

Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Minerva Neurosciences (NERV) Stock?

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q1 2020 Results - Earnings Call Transcript

WALTHAM, Mass., March  12, 2020  (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat unmet medical needs of central nervous system (CNS) disorders, wishes to address a sharp reduction of its share price and subsequent brief trading halt of its shares occurred this morning.

MINERVA NEUROSCIENCES UPDATES MARKET ON SHARE PRICE DROP AND TRADING HALT

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q4 2019 Results - Earnings Call Transcript

Data readout expected in the second quarter of 2020 Data readout expected in the second quarter of 2020

Minerva Neurosciences Announces Completion of Patient Enrollment in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia  

Top-line results expected in the second quarter of 2020 Top-line results expected in the second quarter of 2020

Minerva Neurosciences Announces Completion of Patient Screening in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Shares of Minerva Neurosciences NERV, -19.45% fell 20% in afternoon trading after it said a mid-stage trial for its experimental depression treatment did not meet its primary or secondary endpoints.

Minerva shares fall on failed depression drug trial

Testifying to the tough development pathway for central nervous disorder drugs, another biotech announced a failed study of its experimental drug to treat major depressive disorder, or MDD, and also said it's shelving the clinical program, sending shares sharply lower.

Minerva Neurosciences Shelves Depression Drug Study After Failed Mid-Stage Trial

Minerva's shares are crumbling today on the heels of a major clinical setback.

Why Minerva Neurosciences Stock Is Cratering Today

ACADIA Pharma

Karuna Therapeutics Inc

Neurocrine Biosciences

4 Biotech Neurology Stocks, As Biotechs March On

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q3 2019 Results - Earnings Call Transcript

News for Minerva Neurosciences Stock (NERV)